Vaso (VASO) AI Stock Analysis

• Market Cap: $22.31M
• Dividend Yield: N/A
• Average Volume (3M): 86.61K
• Price to Earnings (P/E): 23.5
• Beta (1Y): 0.16
• Revenue Growth: 7.09%
• EPS Growth: -80.36%
• Country: US
• Employees: 298
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.01
• Shares Outstanding: 175,696,300
• 10 Day Avg. Volume: 62,320
• 30 Day Avg. Volume: 86,609
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.06
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vaso's overall stock score reflects stable financial performance, with consistent revenue growth and a solid balance sheet. However, declines in profitability margins and cash flow efficiency are concerns. Technical indicators show mixed signals, and the stock appears moderately valued. The absence of earnings call or corporate events data limits further insights.

Vaso Business Overview & Revenue Model

Company Description

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

How the Company Makes Money

Vaso Corporation generates revenue through multiple streams. Its primary income is derived from the sale and service of medical devices and diagnostic imaging equipment. Additionally, Vaso earns revenue through its healthcare information technology solutions, which include software and services designed to optimize healthcare operations and improve patient outcomes. The company also benefits from strategic partnerships and collaborations with other technology and healthcare organizations, which help to expand its product offerings and market reach, thus contributing to its overall earnings.

Vaso Financial Statement Overview

Summary

Vaso demonstrates strong revenue growth and effective cash management, despite profitability challenges in the TTM period. The balance sheet remains healthy, with low leverage and solid equity.

Income Statement

Vaso's revenue has shown consistent growth over the past years, although the net profit margin has turned negative in the TTM period due to a net loss. The gross profit margin remains healthy, indicating strong operational efficiency, but the negative EBIT margin in the TTM period highlights challenges in managing operating expenses.

Balance Sheet

Vaso exhibits a solid equity base, with a decreasing debt-to-equity ratio over recent periods, signifying reduced reliance on debt. The return on equity has been strong historically but is impacted in the TTM period due to net losses. The equity ratio remains robust, indicating financial stability.

Cash Flow

Operating cash flow remains positive and relatively stable, although there is a decline in free cash flow growth in the TTM period. The company effectively converts operating cash flows into free cash flow, indicating good cash management practices, despite setbacks in net income.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
81.02M	80.02M	75.58M	69.85M	75.75M
	Gross Profit
50.59M	48.48M	43.13M	38.57M	42.66M
	EBIT
4.20M	7.03M	2.82M	772.00K	1.01M
	EBITDA
5.95M	8.38M	6.66M	3.23M	3.27M
	Net Income Common Stockholders
4.80M	11.87M	6.10M	358.00K	39.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.32M	20.32M	6.65M	7.58M	2.12M
	Total Assets
75.76M	72.66M	52.36M	50.38M	54.36M
	Total Debt
2.06M	1.81M	1.39M	13.19M	13.55M
	Net Debt
-9.28M	-10.01M	-4.64M	6.38M	11.43M
	Total Liabilities
48.91M	49.78M	41.05M	45.29M	48.58M
	Stockholders Equity
26.84M	22.88M	11.31M	5.08M	5.79M
Cash Flow		Free Cash Flow
4.57M	13.85M	7.40M	4.93M	-2.54M
	Operating Cash Flow
5.30M	14.42M	7.82M	5.93M	-1.33M
	Investing Cash Flow
-5.66M	-8.42M	-260.00K	-575.00K	-1.18M
	Financing Cash Flow
-134.00K	-230.00K	-8.33M	-553.00K	1.91M

Vaso Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 75.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VASO.

Vaso Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VASO	62 Neutral	$22.31M	23.52	3.49%	―	7.09%	-80.36%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
VSEE	46 Neutral	$19.21M	―	-3190.66%	―	―	-806.84%
ZCMD	43 Neutral	$29.89M	―	-3.31%	―	-18.37%	71.61%
MSPR	31 Underperform	$18.98M	―	-193.31%	―	24.77%	13.53%

Vaso Corporate Events

Vaso Announces Major Management Changes for 2025

Vaso announced significant management changes effective January 1, 2025. Jane Moen has been appointed as the Chief Operating Officer, while Peter C. Castle will remain as President of VasoTechnology, Inc. Michael Beecher steps down as Co-Chief Financial Officer and Secretary, with Jonathan Newton assuming the role of Chief Financial Officer, Treasurer, and Secretary.